arsenic trioxide / Generic mfg. - LARVOL DELTA

Extramedullary Acute Promyelocytic Leukemia of the Right Proximal Humerus: A Rare Presentation (ASPHO 2025) - "Diagnosis was revised to extramedullary APL, and therefore all-trans retinoic acid (ATRA) was added to her ongoing treatment given patient had already completed 5 days of chemotherapy with cytarabine and daunorubicin...Patient was thereafter switched to treatment as per AAML 1331, which includes the addition of arsenic trioxide infusions to ATRA treatment. This case demonstrates an uncommon presentation of APL in an adolescent patient. It also highlights the need for timely molecular and cytogenetic diagnostic studies in atypical presentations of leukemia to have diagnostic certainty, targeted therapy and improved outcomes for future patients."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Musculoskeletal Pain • Oncology • Pain • Pediatrics • Sarcoma • Solid Tumor • FLT3 • KIT • MPO • PTPRC • SPN • TP53 • WT1

Tragic Transformations and Differentiation Syndrome (ATS 2025) - "This abstract is funded by: None Introduction: Differentiation syndrome (DS) is a life-threatening adverse drug reaction caused by differentiating agents, including all-trans retinoic acid, arsenic trioxide, inhibitors of mutant isocitrate dehydrogenase (e.g., enasidenib), and the FLT3 inhibitor gilteritinib...Case: An 80-year-old female with a history of polycythemia vera and newly diagnosed AML, on decitabine, venetoclax, and enasidenib...Enasidenib was discontinued due to suspected DS, and she was treated with dexamethasone for five days...Despite initial oxygenation improvement with prone positioning, she remained hypotensive requiring norepinephrine, vasopressin, angiotensin II, and hydrocortisone...Leukocytosis worsened, and decitabine and hydroxyurea were initiated due to concern for uncontrolled acute leukemia...Prompt initiation of systemic glucocorticoids is critical in the management of DS, and this condition should be considered in patients receiving active..."

Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Myocardial Ischemia • Oncology • Polycythemia Vera • Renal Disease • Respiratory Diseases • FLT3

Efficient capture and detoxification of gaseous arsenic trioxide from flue gas using silicomanganese alloy dust. (PubMed, J Environ Manage) - "The optimal As2O3(g) capture temperature of SiMnD was 450 °C which was suitable to be applied before SCR with little operating cost. SiMnD was proved to be one excellent capture and detoxification agent for As2O3(g) in flue gas at a lower temperature with promising application prospects."

Journal

Homologous magnetic targeted immune vesicles for amplifying immunotherapy via ferroptosis activation augmented photodynamic therapy against glioblastoma. (PubMed, J Control Release) - "Herein, GBM-derived exosomes (GBM-Exos) co-encapsulate ferroptosis inducer arsenic trioxide (ATO) and NIR photosensitizer IR780, modified with superparamagnetic iron oxide nanoparticle (SPION), to construct homologous magnetic targeted immune vesicles (Sp-Exo/AI) for reinvigorating anti-tumor immunity...Superior anti-tumor effect of Sp-Exo/AI in the recurrence model, breast cancer model and patient-derived model were observed as well. Altogether, the presented homologous magnetic targeted immune vesicles exhibit substantial potential for amplifying immune response in "cold" tumors like GBM through revising immunosuppressive TME."

Journal • Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Solid Tumor

C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma. (PubMed, PLoS One) - "Drug sensitivity analyses identified potential therapeutic agents, including arsenic trioxide, carmustine, vincristine, quercetin, and carboplatin for patients with high C16orf74 expression. These findings highlight the potential of C16orf74 as a biomarker and therapeutic target to improve HNSC management."

Biomarker • IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. (PubMed, Research (Wash D C)) - "Collectively, our findings reveal that a point mutation in the unrearranged PML allele can confer ATO resistance through a protein-protein interaction. Therefore, the unrearranged PML allele should also be screened for drug-resistant mutations in relapsed APL patients."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • RARA

As Many Diseases as They Please: A Case of Respiratory Failure Due to Overlap of Differentiation Syndrome and Staphylococcal Pneumonia (ATS 2025) - "This abstract is funded by: None Introduction: Differentiation syndrome (DS) is a life-threatening complication of acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO)...She had been on prophylactic prednisone for DS which was switched to dexamethasone, and chemotherapy was held...She received vancomycin and cefepime, and was transferred to the ICU...However, the presence of another condition, such as a pneumonia, does not rule out a diagnosis of DS. All patients in the right setting (known malignancy and medication associated with DS) should receive empiric treatment with steroids."

Clinical • Acute Promyelocytic Leukemia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases

Long-term Survival of a Lung Transplant Recipient With Acute Promyelocytic Leukemia and Anatomical Variance in the Donor (ATS 2025) - "The patient's immunosuppressive regimen included prednisone, tacrolimus, and mycophenolate mofetil (MMF)...Induction therapy with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) reduced blast count to 0.4% by day 30...This case highlights a unique instance of long-term survival in a lung transplant recipient with APL who was successfully treated with ATO and ATRA as evidenced by achieving undetectable blast levels. Early and aggressive treatment, along with individualized management, proved essential. Prompt recognition of anatomical variation in the donor's lung and a stepwise approach—such as listing for a re-redo lung transplant when needed—is critical for proactively improving outcomes by addressing potential complications."

Clinical • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Oncology • Otorhinolaryngology • Respiratory Diseases • Transplantation • RARA

Hedgehog signaling pathway inhibitors in the treatment of basal cell carcinoma: An Updated Review. (PubMed, J Drug Target) - "In this review, we summarize BCC's clinical presentation and histopathology and present knowledge on the most studied Hh signaling inhibitors, vismodegib and sonidegib, and other inhibitors of this signaling, such as itraconazole, patidegib, taladegib, and arsenic trioxide, in the treatment of BCC. We also present the most common Hh signaling inhibitor adverse events and their management options, which could improve patients' quality of life during treatment."

Journal • Review • Basal Cell Carcinoma • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Skin Nodular Basal Cell Carcinoma

Synergistic Enhancement of Apo2L/TRAIL and DR4-Induced Apoptosis by Arsenic Trioxide in Triple-Negative Breast Cancer Cells: A Comparison to Conventional Chemotherapy. (PubMed, Cell Biochem Biophys) - "This study investigates whether arsenic trioxide (ATO) can overcome TRAIL resistance by modulating the Apo2L/TRAIL pathway and enhancing the effects of carboplatin (CP) and cyclophosphamide (CY). These findings indicate that ATO sensitizes TNBC cells to TRAIL-mediated apoptosis by upregulating DR4 and Apo2L/TRAIL, while also exhibiting strong synergistic cytotoxicity with CP and CY. This highlights ATO's potential as an adjuvant therapy to improve TNBC treatment efficacy and overcome chemoresistance, warranting further clinical exploration."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Geochemical stability of vitrified glass prepared from arsenic trioxide roaster waste from the Giant Gold Mine (Yellowknife, NT). (PubMed, J Hazard Mater) - "Crushed glasses leach commensurately higher masses of As. The results of this study indicate that vitrifying ATRW decreases its solubility and associated As release."

Journal

Fast pH-Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes. (PubMed, Adv Sci (Weinh)) - "Furthermore, it is shown that solubilized realgar targets PML, displaying wider in vitro therapeutic indices and lower off-target effects than arsenic trioxide, the current APL standard of care. Moreover, in line with evidence of an interplay between PML and HIV persistence, solubilized realgar can disrupt HIV latency, the main barrier to an HIV/AIDS cure, in CD4 T cells of people living with HIV. These findings may open avenues for streamlining realgar solubilization and designing less toxic, orally administrable arsenic-based therapies."

Journal • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Oncology • CD4 • PML • RARA

Antioxidant effects and protective potential of fruit extracts of Detarium microcarpum against arsenic trioxide-induced human lymphocytes DNA oxidative damages. (PubMed, Avicenna J Phytomed) - "The methanol fraction of D. microcarpum fruits have exhibited interesting DNA protection /repair properties probably due to its free radicals quenching ability. Further investigations are necessary to identify the phytomolecules responsible for these biological activities."

Journal

Drug-targeted Mendelian randomization analysis combined with transcriptome sequencing to explore the molecular mechanisms associated with cognitive impairment. (PubMed, J Alzheimers Dis) - "HNMT, TNFSF8, and S1PR5 had 39, 24, and 30 predicted targeted drugs, respectively, including arsenic trioxide, aspirin, and immunomodulators.ConclusionsThis study implicates HNMT, TNFSF8, and S1PR5 as potential therapeutic targets for cognitive impairment. Further validation is required to confirm their clinical relevance."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • HNMT • S1PR5 • TNFSF8

Marking over a century of Auer rods: An illustrated review of acute promyelocytic leukemia. (PubMed, Hematol Oncol Stem Cell Ther) - "However, landmark breakthroughs, particularly the introduction of all-trans retinoic acid in the 1980s and arsenic trioxide in the 1990s, transformed APL into the most curable form of acute leukemia, provided that treatment begins early...We explore modern and practical therapeutic approaches, emphasize risk-adapted treatments, and address major complications, including differentiation syndrome, coagulopathy, and central nervous system involvement. The remarkable evolution of APL-from a highly fatal disease to the most treatable leukemia-highlights how our understanding of disease pathophysiology and biology can transform treatment strategies and improve patient outcomes."

Journal • Review • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology

Germline-p53-mutant adrenocortical carcinoma is a possible candidate for the novel use of arsenic trioxide as a first targeted anticancer therapy for Li-Fraumeni syndrome [WITHDRAWN] (AACR 2025) - "This work provides the first insights in the field on potential germline p53 mutant and cancer candidates for the novel use of ATO as a first targeted antitumor therapy for individuals with LFS."

P53mut • Adrenal Cortex Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • TP53

Investigating druggability of myeloid and lymphoid lineage gene mutations in advanced phase CML by employing drug discovery tools: Implications in fatal blast crisis CML precision oncology (AACR 2025) - "We also found that some FDA-approved drugs for different hematological malignancies (e.g. VENETOCLAX, DECITABINE, AZACITIDINE, BORTEZOMIB, ZANUBRUTINIB, IVOSIDENIB, TAZEMETOSTAT, RUXOLITINIB, PACRITINIB, ARSENIC TRIOXIDE etc.) can effectively target multiple gene groups mutated in our advanced phase CML patients (Table 1-4, Figures 1-4). NGS analysis of AP- & BC-CML found mutations in many AML-/ALL-lineage genes, which is much higher than previously reported. NGS analysis of AP- & BC-CML found mutations in many AML-/ALL-lineage genes, which is much higher than previously reported. This shows a huge genetic similarity between BC-CML and AML/ALL. FDA-approved and various novel experimental drugs under clinical trials are available against some of the genes we reported."

IO biomarker • Metastases • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • AKT1 • BCL2 • DNMT3A • IDH1 • JAK2 • NPM1 • TET2

Arsenoplatin-5: A small molecule that delivers arsenous acid (AACR 2025) - "Arsenic trioxide (ATO), an FDA-approved drug for treating Acute Promyelocytic Leukemia (APL), increased the survival of newly diagnosed and relapsed APL patients. Remarkably, although bearing both platinum and arsenic pharmacophores, AP-5 is significantly less toxic than cisplatin, based on single maximum tolerated dose (MTD) studies in vivo in female C57BL/6 mice. These results demonstrate that AP-5 is a potent, well-tolerated dual pharmacophore agent in vivo and represents the first small molecule capable of delivering an aqueous form of arsenic(III)."

Acute Promyelocytic Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Triple Negative Breast Cancer

A clinically actionable lipid metabolic approach in potentiating the response to anti-androgen therapy in a castration resistant prostate cancer model (AACR 2025) - "Considering that PCa is driven by androgen signaling, and that AR is upstream of lipogenesis and therefore SFA and MUFA production, we aimed to develop a pharmacological approach to sensitize CRPC to treatment, using a combination of the fatty acid synthase (FASN) inhibitor TVB-3664, enzalutamide (ENZ), and the ROS inducer arsenic trioxide (ATO).Experimental Design: We treated castration sensitive (CS) and CRPC cell lines with combinations of TVB, ENZ and ATO and recorded live and dead cell counts. We adopted a therapeutic strategy in rendering CRPC ROS sensitive. Specifically, we used the FASN inhibitor TVB-3664 to elevate membrane PUFA, together with ENZ and the ROS elevating drug ATO. Critically, this clinically actionable combination therapy dramatically decreased the growth of pre-clinical cell lines and PDX models."

Clinical • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Arsenoplatin-7, a family member of arsenoplatins, as a novel therapeutic strategy to overcome platinum-resistance in ovarian cancer (AACR 2025) - "Arsenic trioxide (ATO) is an approved drug for treating acute promyelocytic leukemia, but not in solid tumors...It was hypothesized that APs (AP-1 and AP-7) could have therapeutic effects in cisplatin (CDDP) resistant OC due to the unique nature of the drug delivery...Our preliminary results indicate that AP-7 is a potential therapeutic agent for overcoming platinum resistance in OC by delivering arsenous acid to tumor cells with greater efficacy and less toxicity. However, the prediction of potential target GLI1 warrants further validation."

Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Solid Tumor • GLI1

An unusual and incidental diagnosis of acute promyelocytic leukaemia through eye casualty. (PubMed, J Surg Case Rep) - "The patient successfully completed 29 days of induction all-trans-retinoic acid/arsenic trioxide therapy with repeat bone marrow biopsy showing haematological remission...Retinal haemorrhages may be the initial and only manifestation of APML. A full blood count should be considered in patients who present to eye casualty with haemorrhagic retinopathy of unknown aetiology."

Journal • Acute Promyelocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Macular Edema • Oncology • Ophthalmology • Retinal Disorders

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma (clinicaltrials.gov) - P2 | N=92 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P2 trial • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

A Therapeutic Strategy Integrating Ultrasound-Guided Microwave Ablation with Nanocomposite Hydrogels to Enhance Autophagy and Suppress Tumor Growth in Hepatocellular Carcinoma. (PubMed, Acta Biomater) - "This work repurposes arsenic trioxide (As₂O₃) within a nanocomposite hydrogel delivery system and provides a detailed exploration of its therapeutic mechanisms when combined with MWA therapy. These findings pave the way for advanced clinical strategies in liver cancer management."

Journal • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. (PubMed, Nature) - "Therapies that enable cells to circumvent the differentiation block, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia3, but whether 'differentiation therapy' is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood...Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML."

Journal • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IRF7 • STAT1

Arsenic enhances cervical cancer cell radiosensitivity by suppressing the DNA damage repair pathway. (PubMed, Transl Cancer Res) - "This study aimed to investigate the radiosensitizing effects of arsenic trioxide (ATO) on CC and explore its underlying molecular mechanisms...These findings provide theoretical and experimental support for using ATO as a radiosensitizer in CC therapy, potentially leading to improved treatment outcomes, reduced recurrence rates, and enhanced patient survival. Future research should focus on optimizing ATO's dosage and timing as well as evaluating its long-term safety and efficacy in clinical settings."

Journal • Bloom Syndrome • Breast Cancer • Cervical Cancer • Gastrointestinal Disorder • Metabolic Disorders • Oncology • Primary Immunodeficiency • Solid Tumor • BLM • BRCA1